Summary Background 80% of individuals with cancer will require a surgical procedure, yet little comparative data exist on early outcomes in low-income and middle-income countries (LMICs). We compared postoperative outcomes in breast, colorectal, and gastric cancer surgery in hospitals worldwide, focusing on the effect of disease stage and complications on postoperative mortality. Methods This was a multicentre, international prospective cohort study of consecutive adult patients undergoing surgery for primary breast, colorectal, or gastric cancer requiring a skin incision done under general or neuraxial anaesthesia. The primary outcome was death or major complication within 30 days of surgery. Multilevel logistic regression determined relationships within three-level nested models of patients within hospitals and countries. Hospital-level infrastructure effects were explored with three-way mediation analyses. This study was registered with ClinicalTrials.gov , NCT03471494 . Findings Between April 1, 2018, and Jan 31, 2019, we enrolled 15 958 patients from 428 hospitals in 82 countries (high income 9106 patients, 31 countries; upper-middle income 2721 patients, 23 countries; or lower-middle income 4131 patients, 28 countries). Patients in LMICs presented with more advanced disease compared with patients in high-income countries. 30-day mortality was higher for gastric cancer in low-income or lower-middle-income countries (adjusted odds ratio 3·72, 95% CI 1·70–8·16) and for colorectal cancer in low-income or lower-middle-income countries (4·59, 2·39–8·80) and upper-middle-income countries (2·06, 1·11–3·83). No difference in 30-day mortality was seen in breast cancer. The proportion of patients who died after a major complication was greatest in low-income or lower-middle-income countries (6·15, 3·26–11·59) and upper-middle-income countries (3·89, 2·08–7·29). Postoperative death after complications was partly explained by patient factors (60%) and partly by hospital or country (40%). The absence of consistently available postoperative care facilities was associated with seven to 10 more deaths per 100 major complications in LMICs. Cancer stage alone explained little of the early variation in mortality or postoperative complications. Interpretation Higher levels of mortality after cancer surgery in LMICs was not fully explained by later presentation of disease. The capacity to rescue patients from surgical complications is a tangible opportunity for meaningful intervention. Early death after cancer surgery might be reduced by policies focusing on strengthening perioperative care systems to detect and intervene in common complications. Funding National Institute for Health Research Global Health Research Unit.
Pemilihan obat antidiabetik oral (OAD) pada pasien diabetes melitus tipe 2 (DMT2) dengan penyakit ginjal kronik (PGK) sangatlah penting karena sebagian besar OAD diekskresikan melalui ginjal sehingga diperlukan penyesuaian dosis. Di Indonesia, sulfonilurea (SU) kerja pendek umum dipakai untuk pengelolaan DMT2 dengan PGK. Tinjauan pustaka ini membahas perbandingan efektivitas dan keamanan beberapa jenis SU dengan OAD lainnya pada pasien DMT2 dengan PGK. Golongan obat yang dievaluasi adalah SU, tiazolidindion (TZD), penghambat DPP-IV, dan penghambat SGLT-2. Sulfonilurea kerja pendek (gliklazid dan glipizid) dan penghambat SGLT-2 (empaglifozin dan canaglifozin) dapat menghambat progresi PGK pada DMT2. Pioglitazon dan sitagliptin dikaitkan dengan progresi PGK yang lebih tinggi, sementara linagliptin berefek netral terhadap perburukan PGK. Namun, sitagliptin dan linagliptin memiliki risiko lebih rendah dalam menyebabkan hipoglikemia dibandingkan SU kerja pendek. Dengan demikian, dapat disimpulkan OAD golongan SU kerja pendek, seperti gliklazid dan glipizid masih dapat menjadi pilihan utama untuk pengelolaan glukosa darah pada pasien DMT2 dengan PGK di Indonesia.
Prostate Cancer (PCa) is the third most commonly diagnosed cancer worldwide, and its diagnosis requires many medical examinations, including imaging. Ultrasound offers a practical and cost-effective method for prostate imaging due to its real-time availability at the bedside. Nowadays, various Artificial Intelligence (AI) models, including Machine learning (ML) with neural networks, have been developed to make an accurate diagnosis. In PCa diagnosis, there have been many developed models of ML and the model algorithm using ultrasound images shows good accuracy. This study aims to analyse the accuracy of neural network machine learning models in prostate cancer diagnosis using ultrasound images. The protocol was registered with PROSPERO registration number CRD42021277309. Three reviewers independently conduct a literature search in five online databases (MEDLINE, EBSCO, Proquest, Sciencedirect, and Scopus). We screened a total of 132 titles and abstracts that meet our inclusion and exclusion criteria. We included articles published in English, using human subjects, using neural networks machine learning models, and using prostate biopsy as a standard diagnosis. Non relevant studies and review articles were excluded. After screening, we found six articles relevant to our study. Risk of bias analysis was conducted using QUADAS-2 tool. Of the six articles, four articles used Artificial Neural Network (ANN), one article used Recurrent Neural Network (RNN), and one article used Deep Learning (DL). All articles suggest a positive result of ultrasound in the diagnosis of prostate cancer with a varied ROC curve of 0.76-0.98. Several factors affect AI accuracy, including the model of AI, mode and type of transrectal sonography, Gleason grading, and PSA level. Although there was only limited and low-moderate quality evidence, we managed to analyse the predominant findings comprehensively. In conclusion, machine learning with neural network models is a potential technology in prostate cancer diagnosis that could provide instant information for further workup with relatively high accuracy above 70% of sensitivity/specificity and above 0.5 of ROC-AUC value. Image-based machine learning models would be helpful for doctors to decide whether or not to perform a prostate biopsy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.